FDA Approves New Invokana Drug Amid Lawsuits

This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.

The FDA is not taking the deadly side effects of Invokana seriously. Instead, they approved a new version of the drug. Janssen Pharmaceuticals designed another SGLT2 inhibitor, Invokamet XR to treat Type 2 diabetes. Invokamet XR combines deadly Invokana and metformin to form an extended release version. Even more, people will now be exposed to the serious side effects of Invokana.

Invokana & Ketoacidosis

The most serious being ketoacidosis, which happens when the body produces too much acid in the blood. Symptoms can include difficulty breathing, nausea, vomiting, abdominal pain, confusion and unusual fatigue or sleepiness. Without medical intervention, ketoacidosis can lead to diabetic coma and death.

Ketoacidosis is generally identified in patients with high blood sugar levels and a high number of ketones in their urine. However, doctors have diagnosed the condition in patients taking Invokana without elevated blood sugar levels.

The FDA will release warnings about taking Invokana and demand Janssen to complete additional studies, however they still have not recalled this dangerous drug. Currently, patients fill over 450,000 Invokana prescriptions every three months in the U.S, and now with Invokamet XR that number will rise.

Help for Invokana Victims

When pharmaceutical drugs have affected you, you need an attorney with proven experience taking on companies that receive billions of dollars selling these drugs. If you or a loved one has suffered ketoacidosis or severe kidney problems after taking Invokana, a defender on his side deserve. Call (877) 513-9517 to speak with an attorney in The Michael Brady Lynch Firm about your situation. We will tell you what we can do to help.

Contact us today

Leave a Reply

Your email address will not be published. Required fields are marked *

Contact Us Today

Contact our lawyers directly through the email form below.
  • * Denotes a required field
  • This field is for validation purposes and should be left unchanged.